




The aim of this review is to evaluate the available literature and to calculate a pooled diagnostic 
sensitivity and specificity for the different alpha-defensin test systems to diagnose peri-prosthetic 
infection. 
Materials and Methods 
Studies using alpha-defensin or Synovasure to diagnose periprosthetic joint infection were identified 
from systematic searches of electronic databases. Study quality was evaluated using the QUADAS 
tool. Meta-analysis was completed using a bivariate model. 
Results 
Eleven eligible studies were included. Median QUADAS score was 13 [I.Q.R. 13-13] out of 14. 
Significant conflicts of interest were identified in five studies.  
Pooled sensitivity for the laboratory alpha-defensin test was 0.95 (95% CI 0.91-0.98) and specificity 
0.97 (95% CI 0.95-0.98) for four studies with a threshold level of 5.2mgl-a. Pooled sensitivity for the 
lateral flow cassette test was 0.85 (95% CI 0.74-0.92) and specificity was 0.90 (95% CI 0.91-0.98). 
There was a statistically significant difference in sensitivity but not specificity. 
Conclusion 
Laboratory based alpha-defensin testing remains a promising tool for diagnosing periprosthetic joint 
infection. The lateral flow cassette has a significantly lower performance and pooled results are 
comparable to the leucocyte esterase test. Further studies are essential before the widespread 
adoption of the lateral flow cassette alpha-defensin test.  
 
Take home message 
Alpha defensin testing for periprosthetic joint infection has excellent sensitivity and specificity when 
performed in a laboratory.  
The pooled sensitivity and specificity is much lower when results are combined for the lateral flow 







Infection was the cause for revision in 13,801 (11%) of the 130,195  revision hip or knee 
arthroplasties completed in the U.K. between 2003 and 20151. Infection represents a devastating 
complication, with significant morbidity, mortality and cost. It has been estimated that the mean 
cost from each revision for infection is over £20,0002. As the incidence of joint arthroplasty 
increases, this burden from infection will also rise3. Reliable diagnosis of infection is vital for patients 
and clinicians to guide treatment decisions. 
The diagnosis of periprosthetic joint infection is challenging. There is no individual gold standard test 
that has robust sensitivity and sensitivity, and hence a combination of investigations is required. In 
the initial Musculoskeletal Infection Society (MSIS) consensus guidelines, infection could be 
diagnosed with either one positive major criterion or four positive minor criteria4. These guidelines 
were adapted and updated in 2013, with one positive major criterion or three minor criteria 
identifying periprosthetic infection5 (Table 1). 
Table 1 MSIS and Updated MSIS Criteria for diagnosis of periprosthetic joint infection 
MSIS (2011) Criteria4 Updated (2013) MSIS Criteria5 
1 major criterion or 4 or more minor criteria 1 major criterion or 3 or more minor criteria 
Major Minor Major Minor 
A sinus tract 
communicating with 
the prosthesis 
Elevated serum ESR 
and CRP 
A sinus tract 
communicating with 
the joint 
Elevated serum ESR 
and CRP 
A single isolated 
pathogen from two or 
more samples from 
the prosthetic joint 
Elevated synovial 
white cell count 
A single isolated 
pathogen from two or 
more samples from 
the prosthetic joint 
Elevated synovial 
white cell count or 
positive leucocyte 
esterase test strip 
 Elevated synovial 
polymorphonuclear 
percentage 
 Elevated synovial 
polymorphonuclear 
percentage 
 Presence of pus in the 
affected joint 
 Isolation of a 
microorganism in a 
periprosthetic sample 
 Isolation of a 
microorganism in a 
periprosthetic sample 
 Positive histological 
analysis of 
periprosthetic tissue 
 Greater than 5 
neutrophils in 5 high 
power field in synovial 




The search for novel biomarkers beyond conventional inflammatory markers (C-reactive protein, 
erythrocyte sedimentation rate (CRP, ESR)) has identified alpha-defensin as a potential diagnostic 
tool6. Alpha-defensin is a group of antimicrobial peptide that disrupts the synthesis of bacterial cell 
walls7. 
The alpha-defensin assay had been developed by CD Diagnostics. The peptide may be measured 
quantitatively with an enzyme linked immunosorbent assay (ELISA) in the laboratory or with a lateral 
flow cassette. The lateral flow cassette has been engineered to be used in hospital by theatre staff as 
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a point-of-care testing system. This has the advantage that a result may be obtained within 10 
minutes of a sample being acquired. 
Previous systematic reviews on the use of alpha-defensin have focused on early efficacy studies. 
Wyatt et al. undertook a review published in 2016 that identified six  eligible studies and reported a 
pooled sensitivity of 100% (95% CI 82-100%) and specificity of 96% (95% CI 89-99%)8. However, four 
out of six studies were published by the same authors.6,9–11. One of these was a re-analysis of 
previously published samples11. Five out of the six studies had funding or financial links to CD 
Diagnostics6,9–12 and none of the included studies evaluated the lateral flow cassette. There was 
significant heterogeneity in the studies and variation in test threshold values. This may have had a 
bearing on the results. 
Xie et al. published a systematic review with a search date of January 2016 and included one 
additional study13. This review calculated a pooled sensitivity of 96% (95% CI 85-99%) and specificity 
of 95% (95% CI 89-98%). Three different threshold values were combined in this analysis and no 
studies were included using the lateral flow cassette. 
Saleh et al. presented a systematic review of all synovial biomarkers for periprosthetic infection14. 
This review only identified three studies that studied alpha-defensin as the search was completed in 
mid-2015. 
The aim of this systematic review was to evaluate the diagnostic utility of alpha-defensin for 
periprosthetic joint infections as previous reviews have not included more recent studies or studies 
using the lateral flow cassette. A sub-group analysis of tests performed with a lateral flow cassette 
(Synovasure device) was performed with studies pooled for sensitivity and specificity if three or 





The protocol for this review was registered with the PROSPERO database, registration number 
CRD4201706926715. The protocol had a minor alteration with the inclusion of a sub-group analysis of 
the lateral flow cassette when it became evident that this was a source of heterogeneity within the 
published studies. 
Search strategy 
Searches were designed with the input from an information specialist (DG). OVID Medline, EMBASE 
and PubMed were searched on 17th January 2018. The search strategies are provided in Appendix 1. 
Bibliographies of included studies and relevant review articles were also searched to identify 
potential additional titles. 
Titles and abstracts were screened by one researcher (BM) to compile a list of potentially eligible 
studies. Final selection and data extraction by two researchers (BM & SD) and conflicts were 
resolved by consensus. Study quality was also evaluated by two researchers (BM & SD) using the 
QUADAS instrument16. Data collection was performed using the Joanna Briggs Institute Data 
Extraction Instrument17. Where required, authors were contacted to confirm details for the meta-
analysis. 
Inclusion and exclusion criteria 
Studies were evaluated to identify all investigations using alpha-defensin to assess infection in 
periprosthetic joints using the original or revised MSIS criteria as gold standard. Conference 
abstracts were excluded, but authors and affiliations were used to identify subsequently published 
articles. 
Data analysis 
Heterogeneity was evaluated using graphical evaluation of forest plots and calculation of I2 statistic 
using MetaDiSc 1.4 (Hospital Universitario Ramón y Cajal, Madrid)18. 
Where studies shared pre-specified test threshold values, meta-analysis was completed using a 
bivariate model to calculate pooled sensitivity and specificity. This was conducted using the MADA 
package for R, according to guidance from the Cochrane Diagnostic Accuracy Group19,20. 
Comparisons between groups were completed with a likelihood ratio test. Forest plots were 
generated in RevMan 5.3 (Cochrane Collaboration, Oxford) without performing meta-analysis for 





PRISMA flow diagram 
Studies identified and excluded are shown in the flow diagram (Figure 4). A total of 179 studies were 
identified through database searches, and six from bibliographies. Following title screening, 30 
studies remained, and 14 studies were subject to full text review. Eleven eligible studies were 
identified for inclusion in the qualitative and quantitative analysis. 
Study characteristics 
The study characteristics of included studies are summarised in Table 3. The total number of 
patients included within these studies was 1063. The total number of positive diagnoses of 
periprosthetic joint infection was 305. 
Three studies that were included in previous systematic reviews were excluded from further 
analysis. Wyatt et al. 8 and Xie et al.13 both included the 2014 paper by Deirmengian et al.10. This was 
excluded as the study re-analysed stored samples. The results from these samples had been 
published in a different paper, which was included in this review9. 
• Xie et al.13 included a series from 1937 samples published by Deirmengian et al. in 201510. This study 
was excluded as the reference standard was bacterial culture results rather than diagnosis of 
infection via either the MSIS or revised MSIS consensus guidelines4,5. 
• Frangiamore et al’s paper on alpha defensin for diagnosis of periprosthetic shoulder infections was 
excluded as the reference test had not been validated as there is no consensus on diagnostic criteria 
for periprosthetic shoulder infection21.  
Participants 
All the studies included patients with previous arthroplasty that were listed for revision. Hip and 
knee arthroplasties were the only joints studied in eight trials6,9,12,22–28.One study included hip, knee 
shoulder and elbow arthroplasties29. 
Reference standard 
MSIS criteria were used in five studies, though specific details regarding culture technique were not 
generally presented6,9,12,24,26. In Frangiamore et al.’s study the original MSIS criteria were adapted, as 
synovial leucocyte count and neutrophil percentage were not evaluated24.  
The revised MSIS criteria were used in six studies. Balato et al. and Kasparek et al. adhered to all 
elements of these criteria23,27, whereas Bonanzinga et al., Suda et al. and Sigmund et al. adapted the 
elements of the criteria. Bonanzinga et al. and Gehrke et al. limited the collection of histology 
samples to those patients in whom infection was deemed to be likely by  multidisciplinary team 
meeting, and they did not evaluate ESR25,28. Suda et al. and Sigmund et al. did not measure synovial 
neutrophil percentage, synovial white cell count or serum ESR22,29.  
Index test 
Six studies used a laboratory-based ELISA to measure alpha-defensin levels6,9,12,24,25,28. Two of these 
investigations calculated a threshold level6,21 while four used predetermined threshold values9,12,24,25. 
Six studies used the lateral flow cassette (Synovasure device) to evaluate alpha-defensin22,23,26,29,28,27. 
Risk of bias and conflicts of interest 
Risk of bias for included studies was low. Median [I.Q.R.] QUADAS score was 13 [13-13] out of 14. 
Risk of bias scores are shown in Table 4. 
Trial kits were provided free of charge by CD diagnostics for four studies12,25,26,28. In other studies, 
trial funding was not described. Five studies reported third-party support, financial incentives or 
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stock options with CD Diagnostics or another commercial party related to the study for one or more 
authors 6,9,12,25,26. Intellectual property directly relating to the study material was identified in one 
study9. 
Pooled results for all studies 
 
 
Figure 1 SROC Curve and forest plot for all included studies. SROC graph shows SROC curves and 95% confidence regions 
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Results from all eleven included studies were pooled. Forest plots and SROC curve are shown in 
Figure 1. There was high heterogeneity as I2 was 61% for sensitivity and 50% for specificity. 
Diagnostic odds ratio was 293 (95% CI 91-952), positive likelihood ratio 21 (95% CI 12-35), and 
negative likelihood ratio 0.1 (0.04-0.2). 
Comparison of lateral flow and laboratory based alpha-defensin tests 
Four studies reported the use of a laboratory based alpha-defensin test with a pre-specified 
threshold value of 5.2mgl—1. Six studies demonstrated results using a lateral flow cassette. 
Comparative SROC curves and Forest plots for these techniques are shown in Figure 2. 
For studies completed using a laboratory test, pooled sensitivity was 0.95 (0.91-0.98) and specificity 
was 0.97 (0.95-0.98). The heterogeneity was very low with an I2 for sensitivity and specificity was 
0.0%. Positive likelihood ratio was 31 (95% CI 18-54) and negative likelihood ratio was 0.05 (95% CI 
0.03-0.1). Diagnostic odds ratio was 1004 (95% CI 326-3087). 
The lateral flow cassette had a pooled sensitivity of 0.85 (0.74-0.92) and specificity of 0.90 (0.91-
0.98). There was a significant difference in the likelihood ratio test between laboratory-based and 
lateral flow tests for sensitivity (p=0.019) but not specificity (p=0.47). The heterogeneity was high 
with an I2 for sensitivity was 62% and 67% for specificity. Positive likelihood ratio was 17 (95% CI 6-






Figure 2 SROC and forest plots curve for studies using a laboratory test (lab test) with pre-specified threshold value of 








Summary of results 
This review has analysed eleven studies examining the diagnostic utility of alpha-defensin in the 
diagnosis of periprosthetic joint infection. The summary of results can be found in Table 5. 
The results have shown that the sensitivity and specificity of alpha-defensin can be excellent, with a 
sensitivity and specificity of 0.95 and 0.97 when using a laboratory ELISA with a threshold value of 
5.2mgl-1, and negligible study heterogeneity between the four relevant reports24,25,28,30. 
The pooled results from the lateral flow cassette showed lower sensitivity and specificity than results 
from the laboratory tests. For trials using with the lateral flow cassette, the pooled sensitivity was 
0.85 and specificity 0.9022,23,26–29. This is contrary to the manufacturer’s data sheet, which states the 
lateral flow cassette has a 100% positive agreement and 96% negative agreement with the 
laboratory test31. In the only study comparing lateral flow results to lab results, Gehurle et al 
demonstrated 95% agreement28. Lateral flow cassettes can be an effective technique for evaluating 
synovial fluid, as demonstrated by Wouthuyzen-Bakker et al using synovial calprotectin with a 
sensitivity of 89% and specificity of 95% for periprosthetic joint infection32. 
The reason for this lower sensitivity when using the lateral flow cassette is unclear. It could be due 
to technical errors in the conduct of the test in theatre compared to the use of a controlled ELISA or 
test undertaken in a laboratory. Point-of-care users may not be so meticulous in quality control and 
performing diagnostic tests as trained laboratory staff33. Patient selection may also play a role in the 
difference. Studies by Deirmengian et al. were completed in the CD Diagnostic lab6,9,12 rather in a 
clinical environment. 
A possible further cause for discrepancy is the involvement of industry in supporting many of the 
most positive studies. These studies did not share a threshold value, so pooled sensitivity and 
specificity was not appropriate. 
The pooled sensitivity and specificity of laboratory-based alpha-defensin testing with a threshold of 
5.2mgl-1 compares very favourably to other biomarkers for periprosthetic joint infection, as shown in 
Table 2. The lateral flow cassette performs with a similar sensitivity and specificity to the leucocyte 
esterase test8 or synovial CRP34, but with significant additional cost. 
Table 2 Pooled sensitivity and specificity of biomarkers for periprosthetic joint infection from recent meta-analyses. CRP: C-
reactive protein. 
Reference Test Sensitivity Specificity 
Xie13 Serum procalcitonin 0.53 (0.24-0.8) 0.96 (0.85-0.99) 
Qu35 Bacteriological culture 0.72 (0.65-0.78) 0.95 (0.93-0.97) 
Wyatt8 Synovial leucocyte esterase 0.81 (0.49-0.95) 0.97 (0.82-0.99) 
Yuan34 Serum CRP 0.82 (0.80-0.84) 0.77 (0.76-0.78) 
Wang36 Synovial CRP 0.92 (0.86-0.96) 0.90 (0.87-0.93) 
Berbari37 Serum IL-6 0.97 (0.93-0.99) 0.91 (0.87-0.94) 
. 
Limitations 
While we are confident that this review has captured all published clinical trials on the use of alpha-
defensin for diagnosis of periprosthetic joint infections, the analysis was limited to published studies. 
We are aware of six conference abstracts where alpha-defensin was evaluated. Two of these studies 
were then published in full and were included in this review38,39. One abstract did not present any 
results but stated findings would be available at the conference40. Martin et al. described a 
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sensitivity of 0.75 (95% CI 0.19-0.99) and specificity of 0.8 (95% CI 0.44-0.97) in 14 patients (4 who 
had positive cultures) against bacterial culture results41. Moore et al. showed 100% sensitivity and 
specificity (95% CI 0.16-1.0 and 0.69-1.0 respectively)42 as did Refaie et al. (95% CI for sensitivity 0.4-
1 and specificity 0.84-1)43. As these unpublished studies had low numbers of patients, it is unlikely 
that there would have been a drastic effect on the result from the meta-analysis. 
A formal test for publication bias has not been completed due to low numbers of identified studies44. 
Visual inspection of the funnel plot (Figure 3) shows that there is reasonable symmetry about the 
midline on the log(diagnostic odds ratio) scale. Three studies are outliers with low diagnostic odds 
ratios. 
An additional cause for concern of bias across the published studies is the prevalence of infection. 
The mean (SD) prevalence of infection in the included studies was 28%. This contrasts to the findings 
from the U.K. Joint Registry, which identified 130,195 revision hip and knee (single or first stage) 
replacements between 2003 and 2015. Of these, 13,801 were revisions for infection (11%)1. While 
this should not change the sensitivity or specificity, it may represent a difference between the 
populations being tested for these studies and the general clinical population in the United Kingdom 
requiring revision arthroplasty. 
 
 
Figure 3 Pyramidal funnel plot of studies identified within this systematic review. Reasonable symmetry is seen around the 
midline with three outlying studies with negative results. A formal test has not been completed due to low numbers. 
Conclusions 
Alpha-defensin testing has excellent sensitivity and specificity when performed by ELISA in Citrano 
Medical Laboratories or using laboratory test kits supplied by the manufacturer. Independent 
studies have not replicated this high sensitivity and specificity, and this may be due to technical 
issues, lack of expertise or the wider use of the lateral flow cassette device. 
We would advise revision arthroplasty surgeons that the sensitivity of alpha-defensin levels may not 
be as robust as demonstrated in earlier reviews. It remains a tool to aid diagnosis and needs to be 
interpreted with the same clinical judgement as other tests. 
Further pragmatic studies are required to evaluate the lateral flow cassette in a clinical environment 
before routine adoption of the device to diagnose periprosthetic joint infection. A sample size 
calculation using the formula presented by Buderer suggests such a study would require to enrol 
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1419 patients undergoing revision arthroplasty assuming a prevalence of 10.6% and accuracy of 
5%45. Such a study would be challenging, but not impossible, with the 7829 revision hips and 5,239 
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PRISMA Study flow diagram 
 
 
Figure 4 PRISMA Study flow diagram 
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Studies included in 
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Characteristics of included studies 
Table 3 Characteristics of included studies. Abbreviations used: MSIS - Musculoskeletal Infection Society; MDT Multidisciplinary team; S/Co Signal/Cut off ratio, TP true positive; FP false 
positive; FN false negative; TN True negative. *1S/Co was identified as 5.2mgl-1 in Deirmengian et al 2014a. 
Study ID Location Sample 
size 
Methodology Index test Reference 
test 
Threshold TP FP FN TN 
Balato 201727 Italy 51 Prospective, consecutive Lateral flow MSIS (2013) Cassette 14 1 2 34 
Berger 201726 Multi-centre, Belgium 121 
Prospective, unclear if 
consecutive  
Lateral flow MSIS (2011) Cassette 33 3 1 84 
Bingham 201412 Mayo clinic, Arizona 61 
Retrospective, 
consecutive 
CD Labs kit MSIS (2011) 7.72mgl-1 19 2 0 40 
Bonanzinga 
201725 
ENDO Klinik, Hamburg 156 Prospective, consecutive CD Labs kit MSIS (2013) 1.0 S/Co* 28 4 1 123 
Deirmengian 
2014a9 
CD Diagnostics 149 
Retrospective, unclear if 
consecutive 
ELISA MSIS (2011) 5.2mgl-1 36 5 1 107 
Deirmengian 
2014b6 
CD Diagnostics 95 
Retrospective, unclear if 
consecutive 






Prospective, unclear if 
consecutive 
ELISA MSIS (2011) 5.2mgl-1 26 2 1 87 




Cassette /  
1.0S/Co* 
73 1 5 94 
Kasparek 201623 Vienna 40 Prospective, consecutive Lateral flow MSIS (2013) Cassette 8 2 4 26 
Sigmund 201629 
Medical University of 
Vienna 
19 
Prospective, unclear if 
consecutive 
Lateral flow MSIS (2013) Cassette 9 2 4 34 
Suda 201722 
BG Trauma Centre, 
Ludwigshafen 






Table 4 Study quality assessment using QUADAS tool. Studies were rated on the following questions:1) Was the spectrum of 
patients representative of the patients who will receive the test in practice? 2) Were selection criteria clearly described? 3) 
Is the reference standard likely to correctly classify the target condition? 4) Is the time period between reference standard 
and index test short enough to be reasonably sure that the target condition did not change between the 2 tests? 5) Did the 
whole sample or a random selection of the sample, receive verification using a reference standard of diagnosis? 6) Did 
patients receive the same reference standard regardless of the index text result? 7) Was the reference standard 
independent of the index test (i.e., the index test did not form part of the reference standard)? 8) Was the execution of the 
index test described in sufficient detail to permit replication of the test? 9) Was the execution of the reference standard 
described in sufficient detail to permit its replication? 10) Were the index test results interpreted without knowledge of the 
results of the reference standard?11) Were the reference standard results interpreted without knowledge of the results of 
the index test? 12) Were the same clinical data available when test results were interpreted as would be available when the 
test is used in practice? 13) Were uninterpretable/intermediate test results reported? 14) Were withdrawals from the study 
explained? 
 QUADAS Question Number 
Total 
Study ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Balato 201727 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 
Berger 201726 1 1 1 1 1 0 1 1 1 1 0 1 1 1 12 
Bingham 201412 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 
Bonanzinga 201725 1 1 0 1 1 1 1 1 1 1 1 1 1 1 13 
Deirmengian a 20149 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 
Deirmengian b 20146 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 
Frangiamore 201624 1 1 0 1 1 1 1 1 1 1 1 1 1 1 13 
Gehrke 201828 1 1 1 1 1 1 1 1 1 1 1 1 1 1 14 
Kasparek 201623 1 1 0 1 1 1 1 1 1 1 1 1 1 1 13 
Sigmund 201629 1 1 0 0 1 1 1 1 1 1 1 1 1 1 12 





Table 5 Summary of results table for the diagnostic accuracy of alpha-defensin for detection of infection in revision joint 
replacement 
Patients/population Painful joint replacements being evaluated for revision 
Prior testing Nil specified except clinical examination 
Settings Hospital departments with revision surgery facilities 
Index test Alpha-defensin ELISA or lateral flow cassette 
Reference test MSIS consensus criteria or modified MSIS criteria 




























With a prevalence 
of 24%, 24 out of 
100 patients will 
have a revision 
for infection.  
 
Of these, one will 
be missed by the 










three of the four 
studies had 
financial links to 
















Of the 24 in 100 
patients with 
infection 4 will be 















Appendix 1:  
Search terms 
OVID MEDLINE 
1. exp Defensins/  
2. defensin.mp. 
3. defensins.mp. 
4. antimicrobial peptide.mp. 
5. antimicrobial peptides.mp.  
6. 1 or 2 or 3 or 4 or 5 
7. exp arthroplasty, replacement/  
8. exp joint prosthesis/ 
9. arthroplasty, subchondral/ 
10. arthroplasty.mp. 
11. arthroplasties.mp. 
12. joint replacement.mp. 
13. joint replacements.mp. 
14. joint prosthesis.mp. 
15. joint prostheses.mp. 
16. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17. exp bacterial infections/ 
18. surgical wound infection/ 
19. prosthesis-related infections/ 
20. prosthesis-related infection.mp. 
21. prosthesis-related infections.mp. 
22. prosthesis infection.mp. 
23. prosthesis infections.mp. 
24. prosthetic joint infection.mp. 
25. prosthetic joint infections.mp. 
26. periprosthetic joint infection.mp 
27. periprosthetic joint infections.mp 
28. peri-prosthetic joint infection.mp 
29. peri-prosthetic joint infections.mp 
30. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 
31. 6 and 16 and 26 
OVID EMBASE 
1. exp Defensin/  
2. defensin.mp. 
3. defensins.mp. 
4. antimicrobial peptide.mp. 
5. antimicrobial peptides.mp.  
6. 1 or 2 or 3 or 4 or 5 
7. exp orthopedic prosthesis and orthosis/  
8. exp arthroplasty/ 
9. exp arthroplasty,prosthesis/ 
10. arthroplasty.mp. 
11. arthroplasties.mp. 
12. joint replacement.mp. 
22 
 
13. joint replacements.mp. 
14. joint prosthesis.mp. 
15. joint prostheses.mp. 
16. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17. exp bacterial infection/ 
18. exp surgical infection/ 
19. exp prosthesis infection/ 
20. exp periprosthetic joint infection/ 
21. prosthesis-related infection.mp. 
22. prosthesis-related infections.mp. 
23. prosthesis infection.mp. 
24. prosthesis infections.mp. 
25. prosthetic joint infection.mp. 
26. prosthetic joint infections.mp. 
27. periprosthetic joint infection.mp 
28. periprosthetic joint infections.mp 
29. peri-prosthetic joint infection.mp 
30. peri-prosthetic joint infections.mp 
31. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 29 or 29 or 30 
32. 6 and 16 and 31 
PUBMED 
(“Defensins”[MESH Term] or “defensin” or “defensins” or “antimicrobial peptide” or 
“antimicrobial peptides”) AND (“arthroplasty, replacement”[MESH Term] or “joint 
prosthesis”[ MESH Term] or “arthroplasty, subchondral”[ MESH Term] or “arthroplasty” or 
“arthroplasties” or “joint replacement” or “joint replacements” or “joint prosthesis” or “joint 
prostheses”) AND (“bacterial infections”[ MESH Term] or “surgical wound infection”[ MESH 
Term] or “prosthesis-related infections”[ MESH Term] or “prosthesis-related infection” or 
“prosthesis-related infections” or “prosthesis infection” or “prosthesis infections” or 
“prosthetic joint infection” or “prosthetic joint infections” or “periprosthetic joint infection” 
or “periprosthetic joint infections” or “peri-prosthetic joint infection” or “peri-prosthetic 
joint infections”) 
 
